Cysteine protease inhibitors as chemotherapy for parasitic infections

• Published in: Bioorganic & medicinal chemistry Vol. 7; no. 4; pp. 639 - 644
• Main Authors: McKerrow, James H, Engel, Juan C, Caffrey, Conor R
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.1999
• Subjects: Animals; Antimalarials - pharmacology; Antiparasitic Agents - pharmacology; Antiprotozoal Agents - pharmacology; Cysteine protease; Cysteine Proteinase Inhibitors - pharmacology; Humans; inhibitor; Leishmania; Leishmania - drug effects; malaria; parasite; resistance; safety studies; Trypanocidal Agents - pharmacology; trypanosome; parasite; Cysteine protease; inhibitor; trypanosome; safety studies; Leishmania; malaria; resistance
• ISSN: 0968-0896; 1464-3391
• DOI: 10.1016/S0968-0896(99)00008-5

Analysis of the evolution, localization and biologic function of papain family cysteine proteases in metazoan and protozoan parasites has provided important and often surprising insights into the biochemistry and cellular function of this diverse enzyme family. Furthermore, the relative lack of redundancy of cysteine proteases in parasites compared to their mammalian hosts makes them attractive targets for the development of new antiparasitic chemotherapy. The treatment of experimental models of parasitic diseases with cysteine protease inhibitors has provided an important ‘proof of concept’ for the use of cysteine protease inhibitors in vivo. Evidence has now accumulated that cysteine protease inhibitors can selectively arrest replication of a microbial pathogen without untoward toxicity to the host. Furthermore, this can be achieved with reasonable dosing schedules and oral administration of the drug. Initial studies have confirmed the efficacy of cysteine protease inhibitors in treatment of Trypanosoma cruzi, Plasmodium falciparum and Leishmania major. Work on Trypanosoma brucei, the agent of African trypanosomiasis, is preliminary but also promising. Target validation studies have shown that biotinylated or radiolabeled irreversible inhibitors specifically bind to the cysteine protease targets thought to represent the major activity within the parasite. In the case of T. cruzi, the effect of inhibitors appears to be predominantly in blocking protease processing. Transfection studies using variant constructs have supported this model. Finally, the generation of null mutants for the multiple protease genes in Leishmania mexicana has provided the first genetic support for the key role of this enzyme family in parasite virulence. Safety studies in rodents and analysis of uptake of inhibitors by parasites and host cells suggest that the selectivity of inhibitors for the parasite targets may reside in the lack of redundancy of parasite proteases, the higher concentration of host proteases in intracellular compartments, and differential uptake of inhibitors by parasites. Attempts to elicit resistance to cysteine protease inhibitors in parasite cultures suggest that mechanisms of induced resistance are independent of resistance to the traditional antiparasitic agents. This suggests that cysteine protease inhibitors may provide an alternative to traditional therapy in drug-resistant organisms. ©